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Background: Breast cancer is a major public health challenge. Organized mammography screening (OS) is
considered one way to reduce breast cancer mortality. EU recommendations prone mass deployment of OS, and
back in 2004, France introduced a national OS programme for women aged 50–74 years. However, in 2012,
participation rate was still just 52.7%, well short of the targeted 70% objective. In an effort to re-address the (in)
efficiency of the programme, the French National Cancer Institute has drafted an expert-group review of the ethical
issues surrounding breast cancer mammography screening.
Discussion: Prompted by emerging debate over the efficiency of the screening scheme and its allied public
information provision, we keynote the experts’ report based on analysis of epidemiological data and participation
rate from the public health authorities. The low coverage of the OS scheme may be partly explained by the fact
that a significant number of women undergo mammography outside OS and thus outside OS criteria. These
findings call for further thinking on (i) the ethical principles of beneficence and non-malfeasance underpinning this
public health initiative, (ii) the reasons behind women’s and professionals’ behavior, and (iii) the need to analyze
how information provision to women and the doctor-patient relationship need to evolve in response to scientific
controversy over the risks and benefits of conducting mammographic screening.
Summary: This work calls for a reappraisal of the provision of screening programme information. We advocate a
move to integrate the points sparking debate over the efficiency of the screening scheme to guarantee full
transparency. The perspective is to strengthen the respect for autonomy allowing women to make an informed
choice in their decision on whether or not to participate.
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A need for an expert group review on the ethics of the
screening programme
In population-based screening, individual benefits are
random and few, as the desired outcome hinges on
collective benefits. Breast cancer screening is offered to
asymptomatic women who may then have to contend with
a sudden change from ‘well’ to ‘ill’, with all the ensuing* Correspondence: gregoire.moutel@parisdescartes.fr
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This outcome can lead to unnecessary examinations,
sometimes with secondary effects in subjects wrongly
diagnosed as “positive”. That said, the success and relevance
of any screening programme hinges on acceptance of a
procedure and compliance with its criteria [1]. Democratic
societies are founded on respect for autonomy, especially
in the medical domain. Today, compulsory and imposed
public health measures may no longer be accepted without
total transparency and understanding.
In its role as the body responsible for deploying the
breast cancer screening policy programme since 2004,
the National Cancer Institute (INCa), a French government
agency, led an expert-group review of the ethical issuesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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emerging debate over the efficiency of the screening
scheme and the allied public information provision,
this work resulted in a report published in late-2012
[2]. The group’s thinking, reported here, was based on
analysis of epidemiological data and OS participation rate
from the French public health authorities. The aim was to
address the ethics issues surrounding international debate
over programme benefits and risks in order to refocus
the information given to women onto greater respect
for autonomy in their decision on whether or not to
participate.
Implementation of the French breast cancer screening
programme
Breast cancer is a major public health challenge. It is the
most common cancer among women in France, accounting
for an estimated 48,763 new cases and 11,886 deaths
in 2012 [3]. According to French National Institute of
Statistics and Economic Studies (INSEE), breast cancer
incidence increased 1.4% per year over the 1980–2012
period (Figure 1) [3,4].
Organized mammography screening (OS) is considered
one way to reduce breast cancer mortality [5]. EU
recommendations advocate broad deployment of OS
[6]. France introduced OS throughout the country in
2004 under the First and Second French Cancer Plans
(2003–2007 and 2009–2013). Based on recommendations
in response to the risk factors (gender and age), the
programme invites women aged 50–74 years to attend
screening (breast examination and a mammography)
every two years. The scheme was established according to
specifications and good practices, including double reading
of each negative mammogram and, when necessary, an
ultrasound examination. The screening programme is
organized at regional level by management centres that
send out individual postal invitations inviting women to
participate by attending accredited radiological centres.
The invitation letter does not specify any pre-definedFigure 1 Evolution of mortality and incidence rates (1/100,000) in Fraappointment date ― women are free to make an appoint-
ment in a list of accredited centres enclosed with the letter
of invitation. The principle of informed decision-making
is thus respected. Non-responder or non-participating
women get a follow-up letter within the next six months.
Results are handled and monitored by the manage-
ment centres. The process targets a population of nearly
9 million women, excluding those presenting a high
risk of breast cancer due to family history, genetic
predisposition, personal history of thoracic irradiation
or at-risk of benign tumours.
Discussion
Questions arising from the programme participation rate
Participation rate is one indicator for assessing the
performance of a screening programme. Based on epi-
demiological data and experts’ consensus recommendations,
European guidelines set a target OS participation level of
70% as acceptable whereas 75% is the desirable level [7].
The 70% target level was set on the basis that a high rate
of participation among invited women was necessary in
order to maximize the mortality benefits of population-
based breast cancer screening in a cost-effective man-
ner. However, according to French Institute for Public
Health Surveillance (InVS) data, participation in the
French OS programme was only 52.7% in 2012, with
no significant increase recorded since 2007 (Figure 2)
[8]. The data also highlight strong regional disparities, with
rates ranging from 67.6% in the Loire-Atlantique region
down to 27.6% in Paris. Fifty-four French départements
report over 55% participation, while 21—including six of
the eight départements of the Greater Paris region—report
less than 50% participation.
However, a significant number of mammographies that
should be performed in OS are still prescribed outside the
programme, and thus outside the OS inclusion criteria
(Figure 3) [9]. Mammographies performed outside OS
and its criteria should not normally involve women other
than those presenting high risk factors (family history,nce from 1980 to 2012 [3,4].
Figure 2 OS participation (%) by age bracket [8].
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irradiation or at-risk benign tumours) or those with
clinical symptoms. Among the women aged 50–74
who undergo mammographies outside OS, only 7–8%
would be diagnosed or monitored as belonging to the
high-risk population, which leaves more than 90%
that would otherwise meet the OS criteria. As these
extra-OS procedures are performed outside accredited
management centres, the data does not enter into the
epidemiological evaluation of OS, which thus further
lowers the OS participation rate. Under the French
health insurance system, mammographies are always
reimbursed, which may explain why a number of
women meeting the criteria do not opt into the OS
programme.
The 2011 report from the French National Authority for
Health (HAS) [9] singled out limitations to maintaining
this situation in terms of public health and medicalFigure 3 Mammography participation (%) by age bracket under orga
procedures from 2008 to 2009 [9].effectiveness. Indeed, it was shown that a full transition to
OS was preferable in terms of both number of cancers
detected and costs involved. Further, the OS programme
corresponds to standardized procedures, including
traceability for epidemiological analysis, quality of radio-
logical apparatus, and double reading of radiographies.
Mammographies performed outside OS do not offer the
same level of guarantees in a process that is not evaluable
and thus less legitimate. The same report [9] also showed
that in the absence of double reading of radiographies,
1.4% of abnormal images were missed, there was a higher
rate of false-negatives, and OS screening structures were
underused which reduces the efficiency of the programme.
Furthermore, mammographies performed outside OS
incur additional collective costs, as all health expenditures
in France are reimbursed by the healthcare system. This is
a situation specific to France, which has opted not to
apply pressure to participate in OS and not to financiallynized breast cancer screening (OS) and individual detection
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outside the OS. This, again, is part of a policy designed to
respect the principle of autonomy, and also part of a
continuum, as many women have already had a mammog-
raphy without medical indications before reaching their
50s, and the community reimburses them.
The issue is rooted in a medical-economic dimension, at
a time when the solidarity-based national insurance
system supporting these non-OS practices is facing
increasing pressure.
Our group emphasized the need to raise women’s
awareness of the importance of the criteria established
in the OS programme, both in terms of age and intervals
between examinations and in terms of the quality of
the procedures for accreditation, all of which is linked to
benefit/risk ratio. It is clearly important that communica-
tion to candidate participants should stress these elements.
Barriers to participation in organized screening
Studies in the French context [10,11] have identified
a number of barriers to participation, some of which
explain why a number of women do not undergo
mammographies:
 The feeling of not being concerned, due to an
absence of symptoms and feeling healthy;
 The sense of fatalism over cancer and the belief that
it is impossible to prevent its outcome;
 Lack of time for personal healthcare (for social,
family or medical reasons);
 Other life constraints or priorities (day-to-day,
housing problems, etc.);
 Absence of regular follow-up by a medical gynae-
cologist or GP;
 Women foregoing basic healthcare for financial
reasons are less likely to participate in screening;
 Language barrier and lack of knowledge of the
healthcare system.
 A study by Duport [11] in 2008 ruled out low
geographical accessibility to a radiologist as a
problem due to the existence of neighbourhood
health structures in France.
Other barriers explain why a number of women do
not switch to OS:
 Lack of a clear distinction between diagnostic and
screening mammographies;
 Perception of OS as a highly impersonal procedure
managed by an administrative apparatus with
poorly-identified structures, and the negative view
some people have of any publicly-run process;
 Organizational issues (especially lack of flexibility
when making appointments, etc.). The feeling of not being concerned, due to
perceptions that the programme is a social provision
targeting financially disadvantaged people;
 The preference for a personal relationship with a
physician rather than being invited by mail by the
management centres in charge of the OS
programme.
Our group underlined the importance of targeting
the information according to these two categories of
barriers. For the first category, the accent should be
placed on educating the target audience on cancer,
screening and access to the healthcare system. For the
second category, the focus should be on the specificities of
the OS programme and on the importance of respecting
the OS-framework criteria.
This conclusion challenges both the content of the
tools used in the information campaigns and the place
given to physicians (GPs and/or gynaecologists) in the
OS process, which as a group had not been sufficiently
involved in organizing the OS programme at its outset.
Controversies over the benefit-risk ratio
Debate over the level of efficacy of screening continues to
rage, and scientific controversy surrounding overdiagnosis
and overtreatment raises further questions over the whole
communication strand of the OS system. Historically,
the efficacy of breast cancer screening in terms of
reducing mortality was established based on the results of
randomized trials [5], and was only later brought into
question [12,13]. These trials aimed to investigate not just
the impact of screening on breast cancer mortality but
also the evolution of risks inherent to screening, e.g.
false-negatives as well as false-positives. More than 10
randomized trials carried out in various countries
since 1963 showed that OS led to a relative reduction
in breast cancer mortality of 15–32% after 7–10 years
of follow-up in the 50–69 age group enrolled in these
trials. However, in the early 2000s, fresh analysis
sparked major controversy by showing methodological
weaknesses in some of these trials and challenging
the extent of the benefit claimed in terms of reduced
breast cancer mortality [14,15]. A re-analysis of results by
the US Preventive Task Force in 2009 [16] based on nine
trials showed a 14% reduction in mortality for the 50–59
age group and a 32% reduction for the 60–69 age group.
Other studies in the last 20 years have estimated how far
screening has helped reduce breast cancer mortality in
their populations [17-22], but with results that put the
reduction directly attributable to screening at 3–20%
depending on the country. According to a 2012 UK study
[23], the number of women who need to be screened
every 2 years for 10 years to avoid one death is 1610 for
women aged 45–55 and around 750 for women over 60.
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full report on the benefits and harms of screening as
commented on by leaders in the field in the same
issue of the journal. All these studies, and the reported
uncertainties, serve to fuel the controversy surrounding
the efficacy of screening.
The benefits of breast cancer screening have to be
balanced against its harms, particularly overdiagnosis—
which is defined as cases where screening detects a cancer
that would not have become clinically apparent in the
woman’s lifetime had she not been screened—and
false-positive results—which occur when mammographic
images are wrongly diagnosed as positive (possible
malignancy). In both cases, further examinations then
become necessary that are liable to cause adverse effects
and distress to patients. This can lead to unnecessary
treatments and even mutilation (mastectomy), and thus a
reduction in quality of life. Estimated overdiagnosis rates
vary greatly from one country to another. A study using
the Isère département cancer registry in France estimated
that overdiagnosis in cancer detected by mammography
screening only was 3.3% for invasive cancers and 31.9%
for in situ carcinomas [25]. A review from an independent
UK panel on breast cancer screening stressed that for
every breast cancer death prevented, about three overdiag-
nosed cases will be identified and treated [23]. Puliti et al.
[26] reported that estimations contain a number of
“biases” and variability criteria and concluded that overdi-
agnosis in mammographic screening for breast cancer in
Europe is somewhere in the range 1% to 10%. However,
overdiagnosis rate was estimated at 29% in the Cochrane
review [27] and at 52% in a systematic review of countries
with OS programmes [28]. For false-positives, a recent
literature review showed that the estimated risk in women
aged 50–69 ranges from 8% to 21% in Europe [29].
Interval cancers, i.e. cancer diagnosed between successive
mammographies, are also an important concern, whether a
tumour is present but not detected (false negative) or
whether a fast-growing tumour appears between screening
rounds. In France, two-year interval cancer rate was
estimated at 15.3 per 10,000 women screened in 2004
in the OS programme with two-view mammography
[30]. The existence of interval cancers may influence
both patients’ and health professionals’ perceptions
and trust in the benefit of the screening programme, and
may make it necessary to give specific information on the
uncertainties involved. Participation does not necessarily
imply knowledge and understanding of all the aspects
involved in a screening procedure [31].
Finally, the potential damaging effects linked to irradi-
ation and the existence of radio-induced cancer also have
to be factored in. While the risk exists, it appears to be
low [32]. Efforts to quantify radiation-induced cancers
following participation in breast cancer mammographyscreening remain controversial and difficult to produce.
Epidemiological studies on this topic have mainly
consisted in predicting numbers of radiation-induced
cancers. It was found that the risk of cancer associated
with mammographic irradiation is higher when exposure
occurs at younger ages but decreases with increasing age
[33]. Finally, the EU directive on ‘health protection of
individuals against the dangers of ionizing radiation
through medical exposure’ states that medical exposure
has to be justified and is therefore prohibited in the
absence of any indication [34]—a recommendation that,
in practice, is evidently not always followed.
On the issue of the balance between benefits and risks,
our group underlined the importance of revising the
information given to women so as to integrate the
context of uncertainty, particularly the uncertainty tied
to overdiagnosis and the existence of interval cancers.
Between promotion and information on screening
Women have a fairly positive perception of breast cancer
screening [11,35] thanks to the communication efforts
pioneered by the media, health authorities and physicians.
However, growing concern over possible harm from breast
cancer screening have spurred calls to provide more
balanced and unbiased information to ensure respect
for autonomy and the principle of informed choice [36].
Optimizing informed choice for women thus requires
an evolution in the information delivered both by
professionals and via national campaigns.
It has been shown that successful implementation of OS
is heavily reliant on physicians, who play a key role in
counselling women [11,37]. It is thus vital for health
professionals themselves to be well informed so that they
can pass on valid up-to-date data. A recommendation from
the French health authorities [HAS] in 2011 [9] stressed
the need for health professionals to get refresher training
on the content of the information to be delivered to
women. This should optimize balanced information and
help avoid a one-sided positive discourse on screening.
Our group of experts underlined that the information
delivered to candidate women must include all potentially
negative effects of screening. Any contrary approach would
be unacceptable. Thus, in the 2013 campaign on informa-
tion for breast cancer screening, the leaflet produced by
the INCa included a new section describing the potential
undesirable effects [38]. The brochure was designed by the
communication department in association with patient
organizations, with our group’s coordinator relaying their
recommendations. The innovation lies in the paradox
where those in charge of promoting OS are at the same
time responsible for designing the information that may
prompt women to elect not to participate. The brochure
describes the main benefits of participation as the
estimated 15–21% reduction in breast cancer mortality
Moutel et al. BMC Medical Ethics 2014, 15:64 Page 6 of 8
http://www.biomedcentral.com/1472-6939/15/64and the quality of the medical monitoring involved. The
risks were introduced in the leaflet under a chapter
headed “drawbacks”. First, this “drawbacks” section states
that mammography can detect anomalies requiring
additional tests whereas cancer is not necessarily
diagnosed―a situation referred to as “false positives”.
Second, it states the case for treating slow-evolution
cancer that may have had little or no incidence on
the woman’s life. It explains that as today’s science
cannot dissociate between slow and rapid-evolution
cancers (10 to 20% of all cancers detected); the policy
adopted is to treat all cases, which creates potential
overtreatment. Third, the brochure refers to the existence
of a low risk linked to exposure to irradiation during the
mammography exam. This risk is estimated at 1 to 5
deaths per 100,000 women. Thus, this is the first French
OS promotion campaign to integrate downside elements
of information essential for women to make an informed
choice. This is an evolution designed to instil greater
transparency. This trend is in line with the stance taken
in other countries, such as the UK where the National
Health Service [39] produced a website entitled ‘Informed
choice about cancer screening’ whose content on the
allied benefits and harms was co-constructed with a
citizen “jury” [40]. The website gives access to the latest
scientific data, offers a new approach to developing
information on cancer screening, and proposes a leaflet
including the limits of benefits balanced with the risks that
is sent out with the invitation letter. The balance is also a
trade-off between the risk of having cancer (with a better
prognosis if detected early) and the downside effects
linked to screening. In 2013, a study by Hersch et al. [35]
showed that a number of women would accept a risk
linked to screening (depending on the magnitude of the
overdiagnosis percentage presented to them) and not
change their commitment towards screening.
Between collective interests and individual liberty
These elements strongly echo the biomedical ethics
principles of beneficence and non-malfeasance established
by Beauchamp and Childress [41]. The principle of
beneficence, applied to screening, means that it must
show sufficient benefits (i.e. early detection improves
cancer prognosis) while also contributing to individual
well-being and quality of life rather than only to a reduc-
tion in breast cancer mortality. The principle of non-
malfeasance underlines the need for vigilance on harmful
effects and the obligation to regularly evaluate and
communicate potentially damaging effects through an
analysis of practices, and to do everything possible to
minimize them.
The context of uncertainty raises questions over the
good practices and guidelines to be applied for informing
women. It is important to make the distinction betweenpromotion of screening and information on screening [2].
As the two notions are not mutually exclusive, care should,
however, be taken to not neglect or distort information.
Since the French law of 4 March 2002 [42], patient infor-
mation has been enshrined as a right in a process where
the individual must be able to make an informed choice.
This right is in line with the ethical principle of autonomy,
which requires that physicians and other healthcare profes-
sionals must allow patients to make their own decisions on
healthcare choices, especially for preventive care decisions
[43]. The concept of informed choice takes a different
shape depending on whether the context is screening or
medical care. In the therapeutic approach, the objective is
individual benefit for the patient, and the associated risks
are generally accepted when balanced against the risk of
letting a disease worsen. In breast cancer screening, the
situation is reversed, since to achieve a collective benefit,
individuals have to accept potential risks without being
certain of gaining individual benefit [44].
In any public health action, the benefit sought is
primarily collective, sometimes at the risk of harm to
individuals. Such actions have long been seen as necessarily
ethical, since they are for the greater good of the
population. However, the picture has been shaken up
now that individual risks in public health programmes
are less accepted due to a general attitude moving
away from paternalism and toward a strengthening of
decision-making autonomy and informed choice, which
consequently entails greater transparency on the risks
involved in order to deliver fair information [45]. In this
context, are women irresponsible if they opt out of OS? In
the current state of scientific knowledge, and as long
as OS is seen to have benefits in terms of mortality,
non-participation could be viewed as counter to the wider
public interest. However, as the benefit to the popu-
lation appears to be low and controversial (unlike, for
example, immunization campaigns against measles
and tuberculosis), it appears difficult to stigmatize
non-participating women and invoke the concept of
irresponsibility.
All this illustrates the existence of tension between
the interests or protection of the community, respect
for individual liberty, and citizen responsibility. There is a
political issue centred on criteria guiding the decision
whether or not to promote and maintain an organized
screening programme. This question was recently addressed
by the Swiss Medical Board [46,47] that stressed the need
for a public health programme that does not highlight more
benefits than harms so as to at least provide clear
and unbiased information.
Summary
Organized screening carries stakes tied to the convergence
between users’ rights, public health issues, and notions of
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screening scheme is under debate and thus requires
transparency. The challenge is to provide comprehensive
and intelligible information (including rationale, goals,
notions of collective responsibility, state of scientific
knowledge, and areas of uncertainty over the benefit-risk
balance) enabling women to make an informed choice on
whether to participate in the programme without add-
ing confusion or hampering the public health objective of
reducing breast cancer mortality.
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